Checkpoint Therapeutics, Inc.
|Number of Estimates|
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.
Market Cap: 116 Million
Primary Exchange: NASDAQ
Shares Outstanding: 48.1 Million
Float: 40.5 Million
Sector: Health Technology
Industry: Pharmaceuticals: Major
Longest drawdown: 900 trading days
From: 2017-01-11 To: 2020-06-03
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|